The research behind POLEX.

• Evolution of resistance to irinotecan in cancer cells involves topoisomerase-guided mutations in the non-coding genome that reduce the chances of DNA breaks
  Kumar S, Gahramanov V, Yaglom J, Patel S, … Sherman MY · Int. J. Molecular Sciences · 2023
• Resistance to TOP-1 inhibitors: good old drugs still can surprise us (review)
  Kumar S, Sherman MY · Int. J. Molecular Sciences · 2023
• Cancer cell's Achilles heels: considerations for the design of anti-cancer drug combinations
  Gahramanov V, … Kumar S, … Sherman MY · Int. J. Molecular Sciences · 2024
• A cell double-barcoding system uncovers clonal-specific anti-cancer drug effects in tumours and metastasis
  Hesin A, Kumar S, Gahramanov V, … Sherman MY · Cancers · 2022
• Search for synergistic drug combinations to treat chronic lymphocytic leukaemia
  Hezkiy EE, Kumar S, Gahramanov V, … Sherman MY · Cells · 2022
• Cytoplasmic proteotoxicity regulates HRI-dependent phosphorylation of eIF2α via the HSP70-BAG3 module
  Patel S, Kumar S, Hesin A, Yaglom J, Sherman MY · iScience · 2022

Full publication list and citations: orcid.org/0000-0003-1744-337X